Video

Dr. Paulson on the Utility of Liquid Biopsies Versus Tissue Biopsies

R. Steven Paulson, MD, discusses the utility of liquid biopsies versus tissue biopsies.

R. Steven Paulson, MD, physician, Texas Oncology, discusses the utility of liquid biopsies versus tissue biopsies.

Although tissue biopsy remains the gold standard in oncology, there may not be enough available tissue to perform a biopsy, explains Paulson. In these cases, a patient may need to undergo an invasive procedure to retrieve more tissue for testing.

Alternatively, a liquid biopsy may alleviate the need for an invasive procedure since it only requires a blood draw, says Paulson. A positive result with a liquid biopsy is relatively reliable; however, a negative test result should not be considered definitive.

Additionally, the turn-around time for a liquid biopsy is faster than a tissue biopsy. Therefore, if a liquid biopsy is positive, patients can begin targeted therapy earlier. However, the interpretation of liquid biopsies requires some standardization, concludes Paulson.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic